Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
47.70
+3.06 (6.85%)
At close: Aug 5, 2025, 4:00 PM
47.00
-0.70 (-1.47%)
After-hours: Aug 5, 2025, 7:59 PM EDT

Company Description

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease.

It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates.

The company’s products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer’s disease, alcohol use disorder, and multi-site pain associated with Long COVID.

It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder.

In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2.

Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome.

The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure.

Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding logo
CountryUnited States
Founded2007
IndustryBiotechnology
SectorHealthcare
Employees81
CEOSeth Lederman

Contact Details

Address:
26 Main Street, Suite 101
Chatham, New Jersey 07928
United States
Phone862 799 8599
Websitetonixpharma.com

Stock Details

Ticker SymbolTNXP
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001430306
CUSIP Number890260839
ISIN NumberUS8902608392
Employer ID26-1434750
SIC Code2834

Key Executives

NamePosition
Dr. Seth Lederman M.D.Co-Founder, President, Chief Executive Officer and Chairman
Bradley Saenger CPAChief Financial Officer and Treasurer
Mrs. Jessica Edgar MorrisChief Operating Officer
Dr. Gregory M. Sullivan M.D.Chief Medical Officer and Secretary
Siobhan Fogarty B.Sc., M.Sc.Chief Technical Officer
Joseph Hand Esq., J.D.General Counsel and Executive Vice President of Operations
Dr. Darryl Rideout Ph.D.Executive Vice President of Experimental Chemistry
Dr. Sina Bavari Ph.D.Executive Vice President of Infectious Disease Research and Development
Dr. Zeil Rosenberg M.D., M.P.H.Executive Vice President of Medical
Thomas Englese M.B.A.Executive Vice President of Commercial Operations

Latest SEC Filings

DateTypeTitle
Jul 25, 20258-KCurrent Report
Jul 21, 20258-KCurrent Report
Jul 17, 2025SCHEDULE 13GFiling
Jul 16, 20258-KCurrent Report
Jul 10, 20258-KCurrent Report
Jul 9, 20258-KCurrent Report
Jul 2, 20258-KCurrent Report
Jun 16, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
Jun 12, 2025S-3Registration statement under Securities Act of 1933